(19)

(11)

EP 4 824 055 A1

(12)

(43) Date of publication: 21.10.2026 Bulletin 2026/43 (21) Application number: 24829422.5 (22) Date of filing: 12.12.2024

(51) International Patent Classification (IPC):  C07D 405/08(2006.01) C07D 471/04(2006.01) C07C 233/00(2006.01) (52) Cooperative Patent Classification (CPC): C07D 471/04; C07D 405/08; C07C 235/84 (86) International application number: PCT/EP2024/085943 (87) International publication number: WO 2025/125445 (19.06.2025 Gazette 2025/25)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 12.12.2023 US 202363608874 P 12.12.2023 US 202363609077 P 08.04.2024 US 202463575907 P (71) Applicant: GlaxoSmithKline Intellectual Property (No.3) Limited Stevenage SG1 2NY (GB)

(72) Inventors: CHEN, Heng Collegeville, Pennsylvania 19426 (US) HIGGINS, Tyler Frank Collegeville, Pennsylvania 19426 (US) NILSON, Mark Gregory Collegeville, Pennsylvania 19426 (US) OBLAK, Edward Zachary Collegeville, Pennsylvania 19426 (US) WOODARD, John Lewis Collegeville, Pennsylvania 19426 (US) (74) Representative: Ahern, Jenna Marie  GSK Legal & Compliance - Global Patents 79 New Oxford Street London WC1A 1DG London WC1A 1DG (GB)